CN112592844B - Recombinant pichia pastoris genetically engineered bacterium, construction method thereof and application thereof in xylanase production - Google Patents
Recombinant pichia pastoris genetically engineered bacterium, construction method thereof and application thereof in xylanase production Download PDFInfo
- Publication number
- CN112592844B CN112592844B CN202110029601.5A CN202110029601A CN112592844B CN 112592844 B CN112592844 B CN 112592844B CN 202110029601 A CN202110029601 A CN 202110029601A CN 112592844 B CN112592844 B CN 112592844B
- Authority
- CN
- China
- Prior art keywords
- pichia pastoris
- recombinant
- fermentation
- xylanase
- bacteria
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000894006 Bacteria Species 0.000 title claims abstract description 69
- 241000235058 Komagataella pastoris Species 0.000 title claims abstract description 56
- 101710121765 Endo-1,4-beta-xylanase Proteins 0.000 title claims abstract description 39
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 19
- 238000010276 construction Methods 0.000 title claims abstract description 12
- 238000000855 fermentation Methods 0.000 claims abstract description 74
- 230000004151 fermentation Effects 0.000 claims abstract description 74
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 17
- 101000984121 Homo sapiens Vesicular integral-membrane protein VIP36 Proteins 0.000 claims abstract description 13
- 238000010353 genetic engineering Methods 0.000 claims abstract description 10
- 108090001090 Lectins Proteins 0.000 claims abstract description 7
- 102100025455 Vesicular integral-membrane protein VIP36 Human genes 0.000 claims abstract description 7
- 239000013612 plasmid Substances 0.000 claims description 24
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 20
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 16
- 239000012634 fragment Substances 0.000 claims description 15
- 239000001888 Peptone Substances 0.000 claims description 11
- 108010080698 Peptones Proteins 0.000 claims description 11
- 235000019319 peptone Nutrition 0.000 claims description 11
- 229960002685 biotin Drugs 0.000 claims description 10
- 235000020958 biotin Nutrition 0.000 claims description 10
- 239000011616 biotin Substances 0.000 claims description 10
- 239000000843 powder Substances 0.000 claims description 10
- 101150058758 LMAN2 gene Proteins 0.000 claims description 8
- 239000013613 expression plasmid Substances 0.000 claims description 7
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 claims description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 4
- 238000010367 cloning Methods 0.000 claims description 3
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 238000012216 screening Methods 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 abstract description 32
- 102000004190 Enzymes Human genes 0.000 abstract description 32
- 230000000694 effects Effects 0.000 abstract description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 24
- 239000002609 medium Substances 0.000 description 23
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 16
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 238000000034 method Methods 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 108020004414 DNA Proteins 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 11
- 241001506991 Komagataella phaffii GS115 Species 0.000 description 9
- CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical group N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- 229920000742 Cotton Polymers 0.000 description 8
- 108010084455 Zeocin Proteins 0.000 description 8
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 8
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 239000004744 fabric Substances 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 230000004913 activation Effects 0.000 description 7
- 230000001580 bacterial effect Effects 0.000 description 7
- 238000001962 electrophoresis Methods 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 7
- 235000019796 monopotassium phosphate Nutrition 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 230000003321 amplification Effects 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 238000003199 nucleic acid amplification method Methods 0.000 description 6
- LWFUFLREGJMOIZ-UHFFFAOYSA-N 3,5-dinitrosalicylic acid Chemical compound OC(=O)C1=CC([N+]([O-])=O)=CC([N+]([O-])=O)=C1O LWFUFLREGJMOIZ-UHFFFAOYSA-N 0.000 description 5
- 238000009835 boiling Methods 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000000137 annealing Methods 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 238000003235 crystal violet staining Methods 0.000 description 3
- 238000004925 denaturation Methods 0.000 description 3
- 230000036425 denaturation Effects 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 238000001976 enzyme digestion Methods 0.000 description 3
- 238000002073 fluorescence micrograph Methods 0.000 description 3
- 238000012257 pre-denaturation Methods 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 239000010802 sludge Substances 0.000 description 3
- 239000008223 sterile water Substances 0.000 description 3
- 238000012795 verification Methods 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 238000009776 industrial production Methods 0.000 description 2
- 230000031700 light absorption Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000008057 potassium phosphate buffer Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000011218 seed culture Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 229920001221 xylan Polymers 0.000 description 2
- 150000004823 xylans Chemical class 0.000 description 2
- JIEKMACRVQTPRC-UHFFFAOYSA-N 2-[4-(4-chlorophenyl)-2-phenyl-5-thiazolyl]acetic acid Chemical compound OC(=O)CC=1SC(C=2C=CC=CC=2)=NC=1C1=CC=C(Cl)C=C1 JIEKMACRVQTPRC-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000609240 Ambelania acida Species 0.000 description 1
- 101100422775 Arabidopsis thaliana SUP gene Proteins 0.000 description 1
- 229920002749 Bacterial cellulose Polymers 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 101100083069 Candida albicans (strain SC5314 / ATCC MYA-2876) PGA62 gene Proteins 0.000 description 1
- 101100106993 Candida albicans (strain SC5314 / ATCC MYA-2876) YWP1 gene Proteins 0.000 description 1
- 101150099705 FLO gene Proteins 0.000 description 1
- 101150054379 FLO1 gene Proteins 0.000 description 1
- 101150090134 FLO11 gene Proteins 0.000 description 1
- 240000000731 Fagus sylvatica Species 0.000 description 1
- 235000010099 Fagus sylvatica Nutrition 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 108010093096 Immobilized Enzymes Proteins 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 101100043636 Oryza sativa subsp. japonica SSIIIA gene Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 101100066906 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) FLO10 gene Proteins 0.000 description 1
- 101100066911 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) FLO5 gene Proteins 0.000 description 1
- 101100446801 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) FLO9 gene Proteins 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 229910021536 Zeolite Inorganic materials 0.000 description 1
- 241000222126 [Candida] glabrata Species 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000005016 bacterial cellulose Substances 0.000 description 1
- 239000010905 bagasse Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000032770 biofilm formation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 208000032343 candida glabrata infection Diseases 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 description 1
- XQGPKZUNMMFTAL-UHFFFAOYSA-L dipotassium;hydrogen phosphate;trihydrate Chemical compound O.O.O.[K+].[K+].OP([O-])([O-])=O XQGPKZUNMMFTAL-UHFFFAOYSA-L 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 229960002679 fentiazac Drugs 0.000 description 1
- 238000005189 flocculation Methods 0.000 description 1
- 230000016615 flocculation Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 150000002337 glycosamines Chemical group 0.000 description 1
- 108010037896 heparin-binding hemagglutinin Proteins 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 230000005732 intercellular adhesion Effects 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 230000000503 lectinlike effect Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 239000004745 nonwoven fabric Substances 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- LJCNRYVRMXRIQR-OLXYHTOASA-L potassium sodium L-tartrate Chemical compound [Na+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O LJCNRYVRMXRIQR-OLXYHTOASA-L 0.000 description 1
- 229940074439 potassium sodium tartrate Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- -1 silk Substances 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 235000011006 sodium potassium tartrate Nutrition 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 239000010907 stover Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 1
- 235000019798 tripotassium phosphate Nutrition 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- 239000010457 zeolite Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4726—Lectins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
- C12N15/815—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2477—Hemicellulases not provided in a preceding group
- C12N9/248—Xylanases
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
- Y02E50/00—Technologies for the production of fuel of non-fossil origin
- Y02E50/10—Biofuels, e.g. bio-diesel
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention discloses a recombinant pichia pastoris genetically engineered bacterium, a construction method thereof and application thereof in xylanase production. The recombinant pichia pastoris gene engineering bacteria are used for over-expressing lectin protein gene LMAN2 in the pichia pastoris. The recombinant strain strengthens the biological film forming capability of pichia pastoris, and solves the problems that the pichia pastoris in the prior art has weak film forming capability and cannot be used for continuous immobilized fermentation. Specifically, under the free fermentation condition, the xylanase enzyme activity of the pichia pastoris genetically engineered bacteria is improved by 48.9% compared with that of the original bacteria; under the single immobilized fermentation condition, the xylanase enzyme activity of the pichia pastoris genetic engineering bacteria is improved by 38.8 percent compared with that of the original bacteria, and the recombinant bacteria can stably and continuously perform immobilized fermentation for at least seven batches to produce enzymes.
Description
Technical Field
The invention belongs to the technical fields of genetic engineering and fermentation engineering, and in particular relates to recombinant pichia pastoris genetic engineering bacteria, a construction method thereof and application thereof in xylanase production.
Background
Xylanase is widely applied in industrial production, such as paper industry, food industry, feed industry, energy industry and the like. The main method of xylanase production is microbial fermentation. The microbial fermentation method has the advantages of wide sources of production raw materials, low cost, less environmental pollution in the production process, easy operation, safety, various strains, large-scale production and the like. Along with the maturation and development of molecular biology technology, the genetic engineering technology is used for carrying out molecular transformation on the strain, so that the strain becomes an effective means for obtaining xylanase high-yield strain at present.
The biological film is widely existed in the nature, and in the biological film forming process, the extracellular polymer secreted by the microorganism is the material basis of the biological film forming, has the characteristic of layered distribution, and plays a key role in the adhesion and aggregation characteristics of the microorganism. Intercellular adhesion between yeast cells is commonly referred to as "flocculation", and adhesion is conferred by a specific cell surface protein "adhesin" that is capable of binding specific amino acids or sugar residues on other cell surfaces or facilitating binding to abiotic surfaces. The phenomenon of yeast biofilm formation has been widely studied in candida or saccharomyces cerevisiae. There are many different yeast adhesins, such as the FLO1, FLO5, FLO9, FLO10 and FLO11 genes of the FLO gene family carried by Saccharomyces cerevisiae, the ALS and EAP genes carried by Candida albicans, the EPA genes carried by Candida glabrata, and the like. Adhesion can be classified into lectin-like adhesion (sugar-sensitive) and sugar-insensitive adhesion, LMAN2 belongs to a lectin gene, which is associated with glycoprotein transport.
Pichia pastoris is used as a eukaryotic expression system for efficiently expressing exogenous proteins, has the advantages of stable heredity, high expression efficiency, post-translational processing of proteins and the like, has important application prospect in industrial production, has very weak biological film forming capability, and is difficult to perform immobilized fermentation, in particular to perform immobilized continuous fermentation. At present, researches on biological film-forming genes in pichia pastoris and immobilized fermentation through biological film-forming adsorption are freshly reported. Therefore, the invention provides a recombinant pichia pastoris genetically engineered bacterium to effectively solve the technical problems.
Disclosure of Invention
The invention aims to: the invention aims to solve the technical problem of providing a recombinant pichia pastoris gene engineering bacterium for over-expressing an LMAN2 gene aiming at the defects of the prior art.
The invention also solves the technical problem of providing a construction method of the recombinant pichia pastoris genetically engineered bacterium.
The invention finally solves the technical problem of providing the application of the recombinant pichia pastoris genetically engineered bacteria.
In order to solve the first technical problem, the invention discloses a recombinant pichia pastoris gene engineering bacterium, which over-expresses lectin protein gene LMAN2 in the pichia pastoris.
Wherein the pichia pastoris is Pichia Pastoris GS115,115.
Wherein the nucleotide sequence of the lectin protein gene LMAN2 is shown as SEQ ID NO. 1.
In order to solve the second technical problem, the invention discloses a construction method of the recombinant pichia pastoris genetically engineered bacterium, which comprises the following steps:
(1) PCR amplifying LMAN2 gene fragment with Pichia pastoris genome as template;
(2) Cloning the LMAN2 gene fragment obtained in the step (1) onto an expression plasmid to obtain a recombinant plasmid;
(3) Linearizing the recombinant plasmid obtained in the step (2), introducing the linearized recombinant plasmid into pichia pastoris, and screening to obtain recombinant pichia pastoris genetic engineering bacteria.
In the step (1), the pichia pastoris is preferably p.pastoris GS115.
In the step (1), the primers used for PCR amplification are a primer 1 and a primer 2, and the nucleotide sequences of the primers are respectively shown as SEQ ID NO.2 and SEQ ID NO. 3.
In step (2), the expression plasmid is preferably pGAPZαA.
In order to solve the third technical problem, the invention discloses application of the recombinant pichia pastoris genetically engineered strain in xylanase production.
Wherein, the recombinant pichia pastoris gene engineering bacteria can produce xylanase by any one of the following modes:
(i) Free fermentation: inoculating recombinant pichia pastoris genetic engineering bacterial sludge into a fermentation medium, and fermenting to obtain xylanase enzyme liquid;
(ii) And (3) fixed fermentation: inoculating recombinant pichia pastoris genetic engineering bacterial sludge into a fermentation medium containing an immobilized carrier, and fermenting to obtain xylanase enzyme liquid;
(iii) Immobilized continuous fermentation: inoculating recombinant pichia pastoris genetic engineering bacterial sludge into a fermentation medium containing an immobilized carrier, and fermenting to obtain xylanase enzyme liquid; after each batch of fermentation is finished, the fermentation broth obtained in the previous batch is replaced by a new fermentation medium, and the fermentation is repeated.
In the process, the recombinant pichia pastoris genetically engineered bacteria mud is obtained by centrifuging recombinant pichia pastoris genetically engineered bacteria seed liquid.
The preparation method of the recombinant pichia pastoris genetically engineered bacteria seed solution comprises the following steps:
(a) Inoculating recombinant pichia pastoris gene engineering bacteria into an activation culture medium, and culturing to obtain an activation solution;
(b) Inoculating the activation solution obtained in the step (a) into a seed culture medium, and culturing to obtain the seed solution of the recombinant pichia pastoris genetically engineered bacteria.
In the step (a), the concentration of each component in the activation culture medium is 10-30g/L of peptone, 5-15g/L of yeast powder, 10-30g/L of glucose and 0.1-5mg/L of biotin; preferably 20g/L peptone, 10g/L yeast powder, 20g/L glucose, and 0.4mg/L biotin.
In step (a), the solvent of the activation medium is water.
In step (a), the culture is carried out at 28-30deg.C and 200-300rpm for 16-24 hr, preferably at 30deg.C and 250rpm for 24 hr.
In the step (b), the concentration of each component in the seed culture medium is 10-30g/L of peptone, 5-15g/L of yeast powder, 5-15g/L, YNB-20 g/L of glycerol, 0.1-1g/L of dipotassium hydrogen phosphate, 1-5g/L of potassium dihydrogen phosphate and 0.1-5mg/L of biotin, preferably 20g/L of peptone, 10g/L of yeast powder, 10g/L, YNB 13.4.4 g/L of glycerol, 0.3g/L of dipotassium hydrogen phosphate, 1.18g/L of potassium dihydrogen phosphate and 0.4mg/L of biotin.
In step (b), the solvent of the seed medium is water.
In the step (b), the culture is carried out at 28-30 ℃ and 200-300rpm for 16-24 hours; preferably at 30℃and 250rpm for 24 hours.
In the above (ii) stationary fermentation and (iii) stationary continuous fermentation, the stationary carrier cotton fiber fabric, nonwoven fabric, polyester fiber, polyvinyl alcohol fiber, zeolite, bacterial cellulose membrane, silk, bagasse and corn stover, or any one or a combination of several thereof; preferably cotton fiber fabric.
Preferably, the immobilized carrier is pretreated, namely, the immobilized carrier is sheared into squares of 2-8cm multiplied by 2-8cm, washed and dried by pure water, soaked in ethanol for 0.5-4h, washed by pure water, and dried after being bathed in boiling water for 10-40 min; preferably, the pretreatment is to cut the immobilization carrier into squares of 4cm×4cm, wash and dry with pure water, soak in ethanol for 1h, wash with pure water, and dry with boiling water bath for 30 min.
Wherein the dosage of the immobilized carrier is 2-80g/L fermentation medium, preferably 40g/L fermentation medium.
In the xylanase-producing fermentation medium, the concentration of each component is as follows: 10-30g/L of peptone, 5-15g/L of yeast powder, 10-20g/L of amino-free yeast nitrogen source (YNB), 0.1-1g/L of dipotassium hydrogen phosphate, 1-5g/L of potassium dihydrogen phosphate and 0.1-5mg/L of biotin; preferably 20g/L peptone, 10g/L, YNB 13.4.4 g/L yeast powder, 0.3g/L dipotassium hydrogen phosphate, 1.18g/L potassium dihydrogen phosphate and 0.4mg/L biotin.
Wherein the solvent of the fermentation medium is water.
Preferably, methanol is added during the fermentation to induce xylanase expression.
Further preferably, methanol is added every 24 hours during fermentation.
Still more preferably, methanol is added in an amount of 0.1-2% v/v of the fermentation medium.
The fermentation temperature is 28-30deg.C, preferably 30deg.C.
The rotation speed of the fermentation is 200-300rpm, preferably 250rpm.
The fermentation time is 3-5d, preferably 4d.
The beneficial effects are that: compared with the prior art, the invention has the following advantages:
the invention constructs a Pichia pastoris gene engineering strain for over-expressing LMAN2 for the first time, strengthens the biological film forming capability of Pichia pastoris, and solves the problems that the film forming capability of the Pichia pastoris is weak and the Pichia pastoris cannot be used for continuous immobilized fermentation in the prior art. Specifically, under the free fermentation condition, the xylanase enzyme activity of the pichia pastoris genetically engineered bacteria is improved by 48.9% compared with that of the original bacteria; under the single immobilized fermentation condition, the xylanase enzyme activity of the pichia pastoris genetic engineering bacteria is improved by 38.8 percent compared with that of the original bacteria, and the recombinant bacteria can stably and continuously perform immobilized fermentation for at least seven batches to produce enzymes.
Drawings
The foregoing and/or other advantages of the invention will become more apparent from the following detailed description of the invention when taken in conjunction with the accompanying drawings and detailed description.
FIG. 1 is a schematic representation of the expression plasmid pGAPZαA-LMAN2.
FIG. 2A is a PCR electrophoresis diagram of a target gene LMAN2, lane M is a DL 5000DNA Marker, and lane 1 is the target gene LMAN2; FIG. B is a PCR electrophoretogram of pGAPZ alpha A vector fragment, lane M is DL 5000DNA Marker, and lane 1 is pGAPZ alpha A vector fragment; panel C is an electrophoretogram of recombinant plasmid pGAPZαA-LMAN2, wherein lane M is DL 5000DNA Marker, and lane 1 is recombinant plasmid pGAPZαA-LMAN2.
FIG. 3 is a verification diagram of recombinant GS115-LMAN2, wherein lane M is DL 1000DNA Marker, and lanes 1 and 2 are resistance gene Zeocin fragments.
Fig. 4 is a fluorescence microscopy image of p.pastoris GS115 starting bacteria and recombinant bacteria, wherein fig. a is a fluorescence microscopy image of starting bacteria p.pastoris GS115 and fig. B is a fluorescence microscopy image of recombinant strain GS115-LMAN 2.
FIG. 5 is a graph showing the experimental results of semi-quantitative determination of the amount of the biological membrane by the crystal violet staining method of the starting strain and the recombinant strain.
FIG. 6 is a graph showing comparison of xylanase activities produced by fermentation of starting and recombinant bacteria.
Detailed Description
The experimental methods described in the following examples are all conventional methods unless otherwise specified; the reagents and materials, unless otherwise specified, are commercially available.
Example 1: construction of an overexpression plasmid for overexpressing the LMAN2 Gene
1. Amplification of the target Gene LMAN 2: using the extracted P.pastoris GS115 genome as a template, the gene LMAN2 was amplified with primer 1 (SEQ ID NO. 2) and primer 2 (SEQ ID NO. 3).
The PCR reaction system is shown in Table 1.
TABLE 1 target gene LMAN2 amplification PCR system
The mixture was dispensed into 25. Mu.L of each tube according to the above-mentioned system.
PCR conditions: 1) Pre-denaturation at 94℃for 5min; 2) Denaturation at 98 ℃,10s; 3) Annealing at 55 ℃ for 5s; 4) Extending at 72 ℃ for 15 seconds for 35 cycles; 5) The temperature is fully 72 ℃ and 10min.
The size of the amplified product of the target gene LMAN2 is 1378bp (SEQ ID NO. 1), and the electrophoresis chart is shown in figure 2A. The PCR product was purified by TAKARA gel recovery kit and used in the subsequent experiments.
2. Extraction of expression plasmid pGAPZ alpha A and target fragment amplification
1) Extraction of expression plasmid pGAPZalpha A: coli TOP 10 glycerol bacteria harboring plasmid pGAPZa were inoculated into 5mL of LB liquid medium (containing 25. Mu.g/mL of Zeocin) and cultured overnight at 37 ℃; collecting cells with 2.0mL centrifuge tube, centrifuging at 10000rpm for 2min, and discarding supernatant; the plasmid pGAPZαA was extracted by the procedure described in the instructions of the AxyPrep plasmid DNA minikit.
2) Amplification of pGAPZ alpha A fragments
pGAPZ alpha A fragment was amplified using the linearized pGAPZ alpha A plasmid as template with primer 3 (SEQ ID NO. 4) and primer 4 (SEQ ID NO. 5).
The PCR reaction system is shown in Table 2.
TABLE 2 amplification PCR System of expression plasmid pGAPZ alpha A
Component (A) | Volume (mu L) | Manufacturing factories |
PrimeSTAR Max Premix(2×) | 25 | TAKARA BIO INC. |
Primer 3 (10. Mu.M) | 2 | Prime organism |
Primer 4 (10. Mu.M) | 2 | Prime organism |
Stencil (pGAPZ alpha A plasmid) | 1 | |
Sterile water | 20 |
The mixture was dispensed into 25. Mu.L of each tube according to the above-mentioned system.
PCR conditions: 1) Pre-denaturation at 94℃for 5min; 2) Denaturation at 98 ℃,10s; 3) Annealing at 50 ℃ for 15s; 4) Extending at 72 ℃ for 10 seconds for 35 cycles; 5) The temperature is fully 72 ℃ and 10min. The PCR product was purified by TAKARA gel recovery kit and used in the subsequent experiments.
The amplified product of pGAPZ alpha A fragment has the size of 2857bp (SEQ ID NO. 6), and the electrophoresis chart is shown in figure 2B. The PCR product was purified by TAKARA gel recovery kit and used in the subsequent experiments.
3. Construction of recombinant plasmids
And (2) connecting the target gene fragment obtained in the step (1) with the pGAPZ alpha A fragment obtained in the step (2) according to the steps of the specification of the ClonExpII one-step cloning kit to obtain the recombinant plasmid pGAPZ alpha A-LMAN2. The ligation reaction system was shown in Table 3, and after 30min in a 37℃water bath, the mixture was immediately ice-bathed for 5min and introduced into competent cells of E.coli DH 5. Alpha. And the ligation reaction system was shown in Table 3.
TABLE 3 ligation reaction System
Component (A) | Volume (mu L) |
PCR products of pGAPZa A vector | 1 |
Target gene LMAN2 | 1.2 |
5*CEⅡBuffer | 4 |
ExnaseⅡ | 2 |
Sterile water | 11.8 |
Totalizing | 20 |
The ligation solution obtained above was transferred into 100. Mu.L of E.coli DH 5. Alpha. Competent cells, resuscitated and plated on LB-resistant plates (25. Mu.g/mL Zeocin), and cultured at 37℃for 12 hours until single colonies were grown.
The single colony of the plate is picked, inoculated in LB liquid medium (25 mug/mL Zeocin) for overnight culture at 37 ℃ for 12 hours, and plasmids are extracted, and sequencing shows that the sequence is correct.
The recombinant plasmid has a size of 4235bp (SEQ ID NO. 7), pGAPZalpha A-LMAN2 is shown in figure 1, and its electrophoresis diagram is shown in figure 2C.
Example 2: construction of Pichia pastoris engineering bacteria over-expressing LMAN2 gene
1. Transformation of recombinant plasmids
Plasmid pGAPZαA-LMAN2 was digested tangentially with AvrII.
The linearization system of the recombinant plasmid pGAPZalpha A-LMAN2 is shown in Table 4.
TABLE 4 linearization System for recombinant plasmid pGAPZ alpha A-LMAN2
The conditions of enzyme digestion are 37 ℃ and 1h, and after the enzyme digestion reaction is finished, the enzyme digestion products are recovered by glue and used for subsequent experiments.
The linearized recombinant plasmid pGAPZαA-LMAN2 was introduced into P.Pastois GS115 competent cells, and the cells were selected on a yeast extract peptone glucose agar medium (YPD) resistant plate (100. Mu.g/mL Zeocin) containing 100. Mu.g/mL Zeocin, and cultured at 28-30℃for 2-3d to give single colonies.
2. Verification of recombinant strain GS115-LMAN2
The single colony is picked, colony PCR is carried out by using a primer 5 (SEQ ID NO. 8) and a primer 6 (SEQ ID NO. 9), and whether the recombinant bacterium genome contains the Zeocin gene fragment is verified.
The PCR reaction system is shown in Table 5.
TABLE 5 colony PCR System of recombinant Strain GS115-LMAN2
Component (A) | Volume (mu L) | Manufacturing factories |
PrimeSTAR Max Premix(2×) | 25 | TAKARA BIO INC. |
Primer 5 (10. Mu.M) | 2 | Prime organism |
Primer 6 (10. Mu.M) | 2 | Prime organism |
Template | 1 | |
Sterile water | 20 |
The mixture was dispensed into 25. Mu.L of each tube according to the above-mentioned system.
PCR conditions: 1) Pre-denaturation at 94℃for 5min; 2) Denaturation at 98 ℃,10s; 3) Annealing at 50 ℃ for 15s; 4) Extending at 72 ℃ for 5 seconds for 35 cycles; 5) The temperature is fully 72 ℃ and 10min. The PCR products were verified with 2.0% nucleic acid gel. The size of the PCR product of the Zeocin gene fragment is 358bp (SEQ ID NO. 10), and the electrophoresis chart of the verification result of the recombinant bacteria is shown in figure 3.
Example 3: film formation characterization detection of biological films
In FIG. 4, A and B are graphs of results of detection by a fluorescence microscope after dyeing with FITC-ConA dye solution, respectively, of the starting strain P.pastoris GS115 and the recombinant strain GS115-LMAN2, and it is obvious that the recombinant strain has a better film forming effect than the starting strain and a larger amount of formed biological film.
FIG. 5 shows a semi-quantitative biofilm assay by crystal violet staining, in which 20. Mu.L of bacterial solutions of the starting strain and the recombinant strain were added to 96-well plates each containing 200. Mu.L of YPD, and the OD570 was measured every 12 hours by crystal violet staining and an enzyme-labeled instrument when the culture was performed for 3-5 days. From the figure, it can be seen that the recombinant strain GS115-LMAN2 has better film-forming effect than p.pastoris GS115.
Example 4: determination of xylanase Activity
1. Drawing of xylose standard curve
And taking a 10mL centrifuge tube, adding each component one by one, and drawing a xylose standard curve.
Wherein, the DNS reagent comprises the following components in each liter: 7.5g of 3, 5-dinitrosalicylic acid, 14.0g of sodium hydroxide, 216.0g of potassium sodium tartrate, 5.0g of phenol, 6.0g of sodium metabisulfite and water as a solvent.
Wherein, each liter of xylose standard solution comprises the following components: 10g of xylose and water as a solvent.
Wherein, each liter of the potassium phosphate buffer solution comprises the following components: 3g of tripotassium phosphate, 11.8g of monopotassium phosphate and water as solvent.
Wherein, the xylose standard curve reaction system is shown in Table 6.
TABLE 6 xylose standard curve reaction system
According to the system, adding each component into a 10mL centrifuge tube one by one; after thoroughly mixing, the mixture was boiled in boiling water for 5min, the reaction mixture was rapidly cooled to room temperature with cold water, distilled water was added to 5mL, the mixture was zeroed with a blank, and the absorbance at 540nm was measured. And (3) taking xylose content as an ordinate and a light absorption value as an abscissa, preparing a standard curve, and fitting a regression equation.
2. Determination of xylanase Activity
Xylanase enzyme activity is determined by a 3.5-dinitrosalicylic acid (DNS) reagent method: the monosaccharides from the hydrolysis of xylan (beech) by xylanase are reacted with 3.5-dinitrosalicylic acid (DNS) reagent in color, absorbance is detected at 540nm using uv spectrophotometry, and the enzymatic activity is quantified by measuring the reducing xylose produced by the enzymatic reaction.
The measurement method is as follows: 25 mu L of an enzyme solution with proper dilution is added into 0.225mL of potassium phosphate buffer solution, then 0.5mL of xylan substrate is added for accurate reaction at 50 ℃ for 15min, 1mL of DNS reagent is added for thorough mixing and boiling for 5min, the reaction solution is rapidly cooled to room temperature by cold water, distilled water is added to 5mL, blank control without adding crude enzyme solution is used for zeroing, and the light absorption value is measured at 540 nm. The enzyme activity is defined as: under the conditions of this assay, the amount of enzyme required to release 1. Mu. Mol of reducing sugar per minute is defined as 1 enzyme activity unit (U/mL).
Example 5: experiment for producing xylanase by free fermentation of recombinant bacteria
1. The activating medium per liter was composed as follows: 20g of peptone, 10g of yeast powder, 20g of glucose and 0.4mg of biotin, and the solvent is water.
The seed medium per liter was composed as follows: 20g of peptone, 10g of yeast powder, 10g of glycerol, 13.4g of YNB, 0.3g of dipotassium phosphate trihydrate, 1.18g of potassium dihydrogen phosphate and 0.4mg of biotin, and the solvent is water.
The fermentation medium per liter comprises the following components: 20g of peptone, 10g of yeast powder, 13.4g of YNB, 0.3g of dipotassium hydrogen phosphate, 1.18g of monopotassium phosphate and 0.4mg of biotin, and the solvent is water.
2. Activating: GS115-LMAN2 was removed from the-80℃refrigerator and 5mL of the activation medium was prepared in a tube with an inoculum size of 50. Mu.L and incubated in a shaker at 30℃for 24h at 250rpm.
And (3) switching: after activation, the mixture was poured into 250mL shake flasks containing 50mL of seed medium, and cultured at 30℃and 250rpm for 24 hours to obtain seed solutions.
Fermentation: the fermentation broth was sub-packed in 500mL shake flasks, with 100mL of liquid loading at 115℃for 20min. Centrifuging the seed solution at 4500rpm for 5min, discarding supernatant, inoculating bacterial mud into fermentation medium, and fermenting at 30deg.C and 250rpm for 4d. The induction of xylanase expression was performed by adding 1% v/v methanol (relative to the volume of fermentation medium) every 24h during fermentation.
3. The enzyme activity of xylanase produced by free fermentation of recombinant bacteria is shown in figure 6.
Example 6: xylanase production experiment by single immobilized fermentation of recombinant bacteria
The fermentation broth of example 5 was added to a pretreated cotton fiber fabric support (40 g/L fermentation medium) and sterilized, the remainder of the procedure being as in example 5. The enzyme activity of xylanase produced by single immobilized fermentation of recombinant bacteria is shown in figure 6.
The pretreatment is to cut cotton fiber fabric into squares of 4cm multiplied by 4cm, clean and dry the cotton fiber fabric with pure water, soak the cotton fiber fabric in ethanol for 1h, clean the cotton fiber fabric with pure water, and dry the cotton fiber fabric in a boiling water bath for 30 min.
Comparative example 1: free enzyme production of original bacteria
The recombinant bacteria inoculated in example 5 were replaced with the starting bacteria P.pastoris GS115, and the enzyme activity of the fermentation product obtained by the detection of the rest steps in example 5 is shown in FIG. 6.
As can be seen from FIG. 6, the xylanase obtained by the free fermentation of the original bacteria has lower enzyme activity compared with the free fermentation of the recombinant bacteria, and the enzyme activity produced by the free fermentation of the recombinant bacteria is 48.9% higher than that of the original bacteria.
Comparative example 2: single immobilized enzyme production of original bacteria
The recombinant bacteria inoculated in example 6 were replaced with the original starting bacteria P.pastoris GS115, and the enzyme activity of the fermentation product obtained by the detection of the rest steps in example 6 is shown in FIG. 6.
As can be seen from FIG. 6, the enzyme activity of the enzyme produced by the single immobilized fermentation of the original recombinant bacterium is improved by 38.8% compared with that of the single immobilized fermentation of the original recombinant bacterium.
Example 7: xylanase production experiment by immobilized continuous fermentation of recombinant bacteria
In the immobilized fermentation process, recombinant bacterial thallus is adsorbed on an immobilized carrier in the first batch, fermentation liquid is poured out after shaking and culturing for 4d, the immobilized carrier adsorbed with the bacterial is left, a new 100mL fermentation medium is poured into the immobilized carrier for the second batch of fermentation, culturing for 4d, and the enzyme activity of xylanase is measured, and the enzyme activity of xylanase is shown in Table 7. The batch immobilization and continuous fermentation were followed by this procedure. The rest of the procedure is the same as in example 6.
Comparative example 3: original bacterium immobilized continuous fermentation enzyme production
The recombinant bacteria inoculated in example 7 were replaced with the original starting bacteria P.pastoris GS115, and the enzyme activities of the fermentation products obtained by the detection of the rest steps in example 7 are shown in Table 7.
As can be seen from table 7, the enzyme production ability of the original bacteria at the fourth lot of immobilized fermentation starts to be significantly reduced as compared with immobilized fermentation of the recombinant bacteria, which is capable of stably and continuously performing at least seven lots of immobilized fermentation. The number of times of continuous immobilized fermentation of the recombinant bacterium can be increased because the film forming capability of the recombinant bacterium is enhanced by over-expressing the LMAN2 gene.
TABLE 7 enzyme Activity (U/mL) of enzyme produced by immobilized continuous fermentation of starting and recombinant bacteria
Batch of | A first part | Two (II) | Three kinds of | Fourth, fourth | Five kinds of | Six kinds of | Seven pieces of |
Bacteria producing | 2899.1 | 2174.3 | 1916.8 | 1291.4 | 883.6 | 591.3 | 502.4 |
Recombinant bacterium | 4024.0 | 3947.7 | 4098.3 | 4172.6 | 4086.1 | 4156.2 | 4013.5 |
The invention provides a recombinant pichia pastoris genetically engineered bacterium, a construction method thereof and an application thought and a method in xylanase production, and the method for realizing the technical scheme is a plurality of methods and approaches, the above is only a preferred embodiment of the invention, and it is pointed out that a plurality of improvements and modifications can be made by a person of ordinary skill in the art without departing from the principle of the invention, and the improvements and modifications are also considered as the protection scope of the invention. The components not explicitly described in this embodiment can be implemented by using the prior art.
Sequence listing
<110> university of Nanjing Industrial science
<120> recombinant Pichia pastoris genetically engineered bacterium, construction method thereof and application thereof in xylanase production
<160> 10
<170> SIPOSequenceListing 1.0
<210> 1
<211> 1378
<212> DNA
<213> lectin protein Gene (LMAN 2)
<400> 1
tgaacaacta tttcgaaacg atgttcaaag gagctaggat cctaatagct ctaatcgtct 60
gcattctttt gtggagtgct gtgtcctaca ctatttcctt cttttcatct ccaagtgact 120
ccaaagttgt taaacaggtt caattggata caatttttga taatgcacag atcaacggat 180
tgctcaacaa cgagatgccc aaccttctca aagtcaacaa gaaactccta caggacttta 240
gcatttcaaa gccatggacc tttgatcaaa ttactgaaaa atttcacatc agaggagctt 300
ctaccatgat tgcaagggat aagattagac tggtcaggga ttctcctcaa caagttgggc 360
tgattcaatc caccaaacag ttggaggttt cgaaatatga gtctacctcg ctggagattg 420
acttcaatat caactttgat gacgatgcga agaaacgtct cagtaagaaa ctttacggag 480
acggtgtagg tgtttggttg agtgaaaatg aactacactc aggcgccgcc ttaggtgttg 540
atgatacaac tttcaagggt gttgctgtgt tgattgatac ttatcaaaat tctccaagtg 600
cctctaaact gggcaaattc cctcgtgtgt ctattcaata ttctcaaggt ggtggttaca 660
tatatgataa gggtcaagat ggaaagtcaa actatgaact cggttattgt aacttgaatc 720
tgaaatactt gaattctcct tcaaaaatga gaataaccta tttgaaagat tcagggtacc 780
tttctttgga ctttggagcc aagaaaaatg gcatgcctgg ctccgaatgg tttaactgtt 840
tcactaaaga gggtgtggtt ttgcctgaaa aagtttactt agcattgagt tctgaatgtg 900
gcgcattaca tcacaactca gacatcctgg gaattgaatg gaacgcttta acggacgaac 960
atggtgacgt gctgtcatct atcagcgacc tttcgaatat actaaatgac gagtatatcg 1020
atgagtatgt tcaaaacgaa agcgaaaatg aagtcaagga aagaattgcc aagcaacgcc 1080
atagaaggct gacaaaagat aaacgtccag aaccagaggc ttctgaaaga aggaaaacag 1140
ctcaacgact aaggaaggca gaggaaaggc tgcgaaggca gcatcgtgaa aataacctaa 1200
acaaatatgg ctatgagtca aggttgacat actttcttca aacagtatgg cttctattaa 1260
aatggacatt tattatcata agctttttgc tagtgggttt tatattgtac aaccgaatcc 1320
gcaagctgaa aaagaaaact ggcggattca ttgtataggt tcgaggtacc gatccgag 1378
<210> 2
<211> 48
<212> DNA
<213> primer 1 (Artificial Sequence)
<400> 2
tgaacaacta tttcgaaacg atgttcaaag gagctaggat cctaatag 48
<210> 3
<211> 45
<212> DNA
<213> primer 2 (Artificial Sequence)
<400> 3
tcgaggtacc gatccgagac ctatacaatg aatccgccag ttttc 45
<210> 4
<211> 21
<212> DNA
<213> primer 3 (Artificial Sequence)
<400> 4
gtctcggatc ggtacctcga g 21
<210> 5
<211> 23
<212> DNA
<213> primer 4 (Artificial Sequence)
<400> 5
cgtttcgaaa tagttgttca att 23
<210> 6
<211> 2857
<212> DNA
<213> amplification products of pGAPZaA fragment (Artificial Sequence)
<400> 6
gtctcggatc ggtacctcga gccgcggcgg ccgccagctt tctagaacaa aaactcatct 60
cagaagagga tctgaatagc gccgtcgacc atcatcatca tcatcattga gttttagcct 120
tagacatgac tgttcctcag ttcaagttgg gcacttacga gaagaccggt cttgctagat 180
tctaatcaag aggatgtcag aatgccattt gcctgagaga tgcaggcttc atttttgata 240
cttttttatt tgtaacctat atagtatagg attttttttg tcattttgtt tcttctcgta 300
cgagcttgct cctgatcagc ctatctcgca gctgatgaat atcttgtggt aggggtttgg 360
gaaaatcatt cgagtttgat gtttttcttg gtatttccca ctcctcttca gagtacagaa 420
gattaagtga gaccttcgtt tgtgcggatc ccccacacac catagcttca aaatgtttct 480
actccttttt tactcttcca gattttctcg gactccgcgc atcgccgtac cacttcaaaa 540
cacccaagca cagcatacta aattttccct ctttcttcct ctagggtgtc gttaattacc 600
cgtactaaag gtttggaaaa gaaaaaagag accgcctcgt ttctttttct tcgtcgaaaa 660
aggcaataaa aatttttatc acgtttcttt ttcttgaaat tttttttttt agtttttttc 720
tctttcagtg acctccattg atatttaagt taataaacgg tcttcaattt ctcaagtttc 780
agtttcattt ttcttgttct attacaactt tttttacttc ttgttcatta gaaagaaagc 840
atagcaatct aatctaaggg cggtgttgac aattaatcat cggcatagta tatcggcata 900
gtataatacg acaaggtgag gaactaaacc atggccaagt tgaccagtgc cgttccggtg 960
ctcaccgcgc gcgacgtcgc cggagcggtc gagttctgga ccgaccggct cgggttctcc 1020
cgggacttcg tggaggacga cttcgccggt gtggtccggg acgacgtgac cctgttcatc 1080
agcgcggtcc aggaccaggt ggtgccggac aacaccctgg cctgggtgtg ggtgcgcggc 1140
ctggacgagc tgtacgccga gtggtcggag gtcgtgtcca cgaacttccg ggacgcctcc 1200
gggccggcca tgaccgagat cggcgagcag ccgtgggggc gggagttcgc cctgcgcgac 1260
ccggccggca actgcgtgca cttcgtggcc gaggagcagg actgacacgt ccgacggcgg 1320
cccacgggtc ccaggcctcg gagatccgtc ccccttttcc tttgtcgata tcatgtaatt 1380
agttatgtca cgcttacatt cacgccctcc ccccacatcc gctctaaccg aaaaggaagg 1440
agttagacaa cctgaagtct aggtccctat ttattttttt atagttatgt tagtattaag 1500
aacgttattt atatttcaaa tttttctttt ttttctgtac agacgcgtgt acgcatgtaa 1560
cattatactg aaaaccttgc ttgagaaggt tttgggacgc tcgaaggctt taatttgcaa 1620
gctggagacc aacatgtgag caaaaggcca gcaaaaggcc aggaaccgta aaaaggccgc 1680
gttgctggcg tttttccata ggctccgccc ccctgacgag catcacaaaa atcgacgctc 1740
aagtcagagg tggcgaaacc cgacaggact ataaagatac caggcgtttc cccctggaag 1800
ctccctcgtg cgctctcctg ttccgaccct gccgcttacc ggatacctgt ccgcctttct 1860
cccttcggga agcgtggcgc tttctcaatg ctcacgctgt aggtatctca gttcggtgta 1920
ggtcgttcgc tccaagctgg gctgtgtgca cgaacccccc gttcagcccg accgctgcgc 1980
cttatccggt aactatcgtc ttgagtccaa cccggtaaga cacgacttat cgccactggc 2040
agcagccact ggtaacagga ttagcagagc gaggtatgta ggcggtgcta cagagttctt 2100
gaagtggtgg cctaactacg gctacactag aaggacagta tttggtatct gcgctctgct 2160
gaagccagtt accttcggaa aaagagttgg tagctcttga tccggcaaac aaaccaccgc 2220
tggtagcggt ggtttttttg tttgcaagca gcagattacg cgcagaaaaa aaggatctca 2280
agaagatcct ttgatctttt ctacggggtc tgacgctcag tggaacgaaa actcacgtta 2340
agggattttg gtcatgcatg agatcagatc ttttttgtag aaatgtcttg gtgtcctcgt 2400
ccaatcaggt agccatctct gaaatatctg gctccgttgc aactccgaac gacctgctgg 2460
caacgtaaaa ttctccgggg taaaacttaa atgtggagta atggaaccag aaacgtctct 2520
tcccttctct ctccttccac cgcccgttac cgtccctagg aaattttact ctgctggaga 2580
gcttcttcta cggccccctt gcagcaatgc tcttcccagc attacgttgc gggtaaaacg 2640
gaggtcgtgt acccgaccta gcagcccagg gatggaaaag tcccggccgt cgctggcaat 2700
aatagcgggc ggacgcatgt catgagatta ttggaaacca ccagaatcga atataaaagg 2760
cgaacacctt tcccaatttt ggtttctcct gacccaaaga ctttaaattt aatttatttg 2820
tccctatttc aatcaattga acaactattt cgaaacg 2857
<210> 7
<211> 4235
<212> DNA
<213> recombinant plasmid (Artificial Sequence)
<400> 7
agatcttttt tgtagaaatg tcttggtgtc ctcgtccaat caggtagcca tctctgaaat 60
atctggctcc gttgcaactc cgaacgacct gctggcaacg taaaattctc cggggtaaaa 120
cttaaatgtg gagtaatgga accagaaacg tctcttccct tctctctcct tccaccgccc 180
gttaccgtcc ctaggaaatt ttactctgct ggagagcttc ttctacggcc cccttgcagc 240
aatgctcttc ccagcattac gttgcgggta aaacggaggt cgtgtacccg acctagcagc 300
ccagggatgg aaaagtcccg gccgtcgctg gcaataatag cgggcggacg catgtcatga 360
gattattgga aaccaccaga atcgaatata aaaggcgaac acctttccca attttggttt 420
ctcctgaccc aaagacttta aatttaattt atttgtccct atttcaatca attgaacaac 480
tatttcgaaa cgttcacacg taatcatcaa cgatgttcaa aggagctagg atcctaatag 540
ctctaatcgt ctgcattctt ttgtggagtg ctgtgtccta cactatttcc ttcttttcat 600
ctccaagtga ctccaaagtt gttaaacagg ttcaattgga tacaattttt gataatgcac 660
agatcaacgg attgctcaac aacgagatgc ccaaccttct caaagtcaac aagaaactcc 720
tacaggactt tagcatttca aagccatgga cctttgatca aattactgaa aaatttcaca 780
tcagaggagc ttctaccatg attgcaaggg ataagattag actggtcagg gattctcctc 840
aacaagttgg gctgattcaa tccaccaaac agttggaggt ttcgaaatat gagtctacct 900
cgctggagat tgacttcaat atcaactttg atgacgatgc gaagaaacgt ctcagtaaga 960
aactttacgg agacggtgta ggtgtttggt tgagtgaaaa tgaactacac tcaggcgccg 1020
ccttaggtgt tgatgataca actttcaagg gtgttgctgt gttgattgat acttatcaaa 1080
attctccaag tgcctctaaa ctgggcaaat tccctcgtgt gtctattcaa tattctcaag 1140
gtggtggtta catatatgat aagggtcaag atggaaagtc aaactatgaa ctcggttatt 1200
gtaacttgaa tctgaaatac ttgaattctc cttcaaaaat gagaataacc tatttgaaag 1260
attcagggta cctttctttg gactttggag ccaagaaaaa tggcatgcct ggctccgaat 1320
ggtttaactg tttcactaaa gagggtgtgg ttttgcctga aaaagtttac ttagcattga 1380
gttctgaatg tggcgcatta catcacaact cagacatcct gggaattgaa tggaacgctt 1440
taacggacga acatggtgac gtgctgtcat ctatcagcga cctttcgaat atactaaatg 1500
acgagtatat cgatgagtat gttcaaaacg aaagcgaaaa tgaagtcaag gaaagaattg 1560
ccaagcaacg ccatagaagg ctgacaaaag ataaacgtcc agaaccagag gcttctgaaa 1620
gaaggaaaac agctcaacga ctaaggaagg cagaggaaag gctgcgaagg cagcatcgtg 1680
aaaataacct aaacaaatat ggctatgagt caaggttgac atactttctt caaacagtat 1740
ggcttctatt aaaatggaca tttattatca taagcttttt gctagtgggt tttatattgt 1800
acaaccgaat ccgcaagctg aaaaagaaaa ctggcggatt cattgtatag gtttgatgta 1860
tgtataggtt gtctcggatc ggtacctcga gccgcggcgg ccgccagctt tctagaacaa 1920
aaactcatct cagaagagga tctgaatagc gccgtcgacc atcatcatca tcatcattga 1980
gttttagcct tagacatgac tgttcctcag ttcaagttgg gcacttacga gaagaccggt 2040
cttgctagat tctaatcaag aggatgtcag aatgccattt gcctgagaga tgcaggcttc 2100
atttttgata cttttttatt tgtaacctat atagtatagg attttttttg tcattttgtt 2160
tcttctcgta cgagcttgct cctgatcagc ctatctcgca gctgatgaat atcttgtggt 2220
aggggtttgg gaaaatcatt cgagtttgat gtttttcttg gtatttccca ctcctcttca 2280
gagtacagaa gattaagtga gaccttcgtt tgtgcggatc ccccacacac catagcttca 2340
aaatgtttct actccttttt tactcttcca gattttctcg gactccgcgc atcgccgtac 2400
cacttcaaaa cacccaagca cagcatacta aattttccct ctttcttcct ctagggtgtc 2460
gttaattacc cgtactaaag gtttggaaaa gaaaaaagag accgcctcgt ttctttttct 2520
tcgtcgaaaa aggcaataaa aatttttatc acgtttcttt ttcttgaaat tttttttttt 2580
agtttttttc tctttcagtg acctccattg atatttaagt taataaacgg tcttcaattt 2640
ctcaagtttc agtttcattt ttcttgttct attacaactt tttttacttc ttgttcatta 2700
gaaagaaagc atagcaatct aatctaaggg cggtgttgac aattaatcat cggcatagta 2760
tatcggcata gtataatacg acaaggtgag gaactaaacc atggccaagt tgaccagtgc 2820
cgttccggtg ctcaccgcgc gcgacgtcgc cggagcggtc gagttctgga ccgaccggct 2880
cgggttctcc cgggacttcg tggaggacga cttcgccggt gtggtccggg acgacgtgac 2940
cctgttcatc agcgcggtcc aggaccaggt ggtgccggac aacaccctgg cctgggtgtg 3000
ggtgcgcggc ctggacgagc tgtacgccga gtggtcggag gtcgtgtcca cgaacttccg 3060
ggacgcctcc gggccggcca tgaccgagat cggcgagcag ccgtgggggc gggagttcgc 3120
cctgcgcgac ccggccggca actgcgtgca cttcgtggcc gaggagcagg actgacacgt 3180
ccgacggcgg cccacgggtc ccaggcctcg gagatccgtc ccccttttcc tttgtcgata 3240
tcatgtaatt agttatgtca cgcttacatt cacgccctcc ccccacatcc gctctaaccg 3300
aaaaggaagg agttagacaa cctgaagtct aggtccctat ttattttttt atagttatgt 3360
tagtattaag aacgttattt atatttcaaa tttttctttt ttttctgtac agacgcgtgt 3420
acgcatgtaa cattatactg aaaaccttgc ttgagaaggt tttgggacgc tcgaaggctt 3480
taatttgcaa gctggagacc aacatgtgag caaaaggcca gcaaaaggcc aggaaccgta 3540
aaaaggccgc gttgctggcg tttttccata ggctccgccc ccctgacgag catcacaaaa 3600
atcgacgctc aagtcagagg tggcgaaacc cgacaggact ataaagatac caggcgtttc 3660
cccctggaag ctccctcgtg cgctctcctg ttccgaccct gccgcttacc ggatacctgt 3720
ccgcctttct cccttcggga agcgtggcgc tttctcaatg ctcacgctgt aggtatctca 3780
gttcggtgta ggtcgttcgc tccaagctgg gctgtgtgca cgaacccccc gttcagcccg 3840
accgctgcgc cttatccggt aactatcgtc ttgagtccaa cccggtaaga cacgacttat 3900
cgccactggc agcagccact ggtaacagga ttagcagagc gaggtatgta ggcggtgcta 3960
cagagttctt gaagtggtgg cctaactacg gctacactag aaggacagta tttggtatct 4020
gcgctctgct gaagccagtt accttcggaa aaagagttgg tagctcttga tccggcaaac 4080
aaaccaccgc tggtagcggt ggtttttttg tttgcaagca gcagattacg cgcagaaaaa 4140
aaggatctca agaagatcct ttgatctttt ctacggggtc tgacgctcag tggaacgaaa 4200
actcacgtta agggattttg gtcatgcatg agatc 4235
<210> 8
<211> 20
<212> DNA
<213> primer 5 (Artificial Sequence)
<400> 8
atggccaagt tgaccagtgc 20
<210> 9
<211> 20
<212> DNA
<213> primer 6 (Artificial Sequence)
<400> 9
ccacgaagtg cacgcagttg 20
<210> 10
<211> 358
<212> DNA
<213> Zeocin
<400> 10
atggccaagt tgaccagtgc cgttccggtg ctcaccgcgc gcgacgtcgc cggagcggtc 60
gagttctgga ccgaccggct cgggttctcc cgggacttcg tggaggacga cttcgccggt 120
gtggtccggg acgacgtgac cctgttcatc agcgcggtcc aggaccaggt ggtgccggac 180
aacaccctgg cctgggtgtg ggtgcgcggc ctggacgagc tgtacgccga gtggtcggag 240
gtcgtgtcca cgaacttccg ggacgcctcc gggccggcca tgaccgagat cggcgagcag 300
ccgtgggggc gggagttcgc cctgcgcgac ccggccggca actgcgtgca cttcgtgg 358
Claims (7)
1. The application of the recombinant pichia pastoris gene engineering bacteria in xylanase production is characterized in that the recombinant pichia pastoris gene engineering bacteria are used for over-expressing lectin protein gene LMAN2 in the pichia pastoris; the pichia pastoris is Pichia Pastoris GS; the nucleotide sequence of the lectin protein gene LMAN2 is shown as SEQ ID NO. 1.
2. The use according to claim 1, wherein the construction method of the recombinant pichia pastoris gene engineering bacteria comprises the following steps:
(1) PCR amplifying LMAN2 gene fragment with Pichia pastoris genome as template;
(2) Cloning the LMAN2 gene fragment obtained in the step (1) onto an expression plasmid to obtain a recombinant plasmid;
(3) Linearizing the recombinant plasmid obtained in the step (2), introducing the linearized recombinant plasmid into pichia pastoris, and screening to obtain recombinant pichia pastoris genetic engineering bacteria.
3. The use according to claim 1, wherein the recombinant pichia pastoris engineered strain produces xylanase by episomal fermentation.
4. The use according to claim 1, wherein the recombinant pichia pastoris engineered strain produces xylanase by means of immobilized fermentation.
5. The use according to claim 1, wherein the recombinant pichia pastoris engineered strain produces xylanase by immobilized continuous fermentation.
6. The use according to claim 4 or 5, characterized in that the amount of immobilized carrier is 2-80g/L fermentation medium.
7. The use according to claim 1, wherein the xylanase-producing fermentation medium comprises the following concentrations of the components: 10-30g/L of peptone, 5-15g/L of yeast powder, 10-20g/L of amino-free yeast nitrogen source, 0.1-1g/L of dipotassium hydrogen phosphate, 1-5g/L of monopotassium hydrogen phosphate and 0.1-5mg/L of biotin.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110029601.5A CN112592844B (en) | 2021-01-11 | 2021-01-11 | Recombinant pichia pastoris genetically engineered bacterium, construction method thereof and application thereof in xylanase production |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110029601.5A CN112592844B (en) | 2021-01-11 | 2021-01-11 | Recombinant pichia pastoris genetically engineered bacterium, construction method thereof and application thereof in xylanase production |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112592844A CN112592844A (en) | 2021-04-02 |
CN112592844B true CN112592844B (en) | 2023-08-18 |
Family
ID=75207022
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110029601.5A Active CN112592844B (en) | 2021-01-11 | 2021-01-11 | Recombinant pichia pastoris genetically engineered bacterium, construction method thereof and application thereof in xylanase production |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112592844B (en) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08270A (en) * | 1994-06-23 | 1996-01-09 | Kirin Brewery Co Ltd | Yeast agglutination gene fl08 |
WO2005021789A1 (en) * | 2003-08-28 | 2005-03-10 | Institut Pasteur | Polypeptides involved in fungal biofilm formation and polynucleotides encoding same and uses thereof |
JP2006174767A (en) * | 2004-12-22 | 2006-07-06 | Kobe Univ | Yeast in genus pichia and method for producing the same |
CN101983240A (en) * | 2008-03-18 | 2011-03-02 | 国立大学法人山口大学 | Flocculent yeast and method for production thereof |
WO2019170892A1 (en) * | 2018-03-09 | 2019-09-12 | Syndermix Ag | Methods and compositions for lectin production |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2256206B1 (en) * | 2008-02-22 | 2015-04-08 | National University Corporation Nagoya University | Method and gene for imparting or enhancing nonspecific adherence and/or aggregability to microorganism |
-
2021
- 2021-01-11 CN CN202110029601.5A patent/CN112592844B/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08270A (en) * | 1994-06-23 | 1996-01-09 | Kirin Brewery Co Ltd | Yeast agglutination gene fl08 |
WO2005021789A1 (en) * | 2003-08-28 | 2005-03-10 | Institut Pasteur | Polypeptides involved in fungal biofilm formation and polynucleotides encoding same and uses thereof |
JP2006174767A (en) * | 2004-12-22 | 2006-07-06 | Kobe Univ | Yeast in genus pichia and method for producing the same |
CN101983240A (en) * | 2008-03-18 | 2011-03-02 | 国立大学法人山口大学 | Flocculent yeast and method for production thereof |
WO2019170892A1 (en) * | 2018-03-09 | 2019-09-12 | Syndermix Ag | Methods and compositions for lectin production |
Non-Patent Citations (1)
Title |
---|
Flocculation, adhesion and biofilm formation in yeasts;Kevin J. Verstrepen,等;《Molecular Microbiology》;20061231;第60卷(第1期);第5-15页 * |
Also Published As
Publication number | Publication date |
---|---|
CN112592844A (en) | 2021-04-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111378679B (en) | Gene expression assembly, cloning vector constructed by same and application of cloning vector | |
Jiayang et al. | Production of 2, 3-butanediol by Klebsiella pneumoniae using glucose and ammonium phosphate | |
CN108085286A (en) | The coltfoal shape bacillus spp. microorganism of cellulose production capacity with enhancing and its method for producing cellulose | |
CN108642109A (en) | A method of improving Corynebacterium glutamicum recombinant protein expression quantity | |
CN1247790C (en) | Method for producing ascorbic acid intermediates | |
KR102276373B1 (en) | Gene therapy DNA vector VTvaf17, production method; E. coli strain SCS110-AF, production method; E. coli strain SCS110-AF/VTvaf17 having gene therapy DNA vector VTvaf17, production method | |
GB2478791A (en) | Ethanol production by genetically-modified bacteria | |
CN112592844B (en) | Recombinant pichia pastoris genetically engineered bacterium, construction method thereof and application thereof in xylanase production | |
CN112592839B (en) | Rhizopus oryzae for degrading ethyl carbamate and application thereof | |
CN108642074A (en) | A kind of plasmid vector containing ethanol inducible promoter and its application in improving Corynebacterium glutamicum recombinant protein expression quantity | |
CN113046256B (en) | Recombinant pichia pastoris genetically engineered bacterium, construction method and application thereof | |
GB2150933A (en) | Pentosan-degrading enzyme | |
CN108070532A (en) | A kind of method for producing glucose oxidase | |
CN114990149B (en) | Vector for traceless editing of target gene, construction and application thereof | |
CN107354189A (en) | Method for purifying proteins based on alpha-hydroxy acid | |
CN109957576A (en) | A kind of pFC330-BEC plasmid being able to achieve the accurate point mutation of base and its application | |
Amin et al. | By-products formed during direct conversion of sugar beets to ethanol by Zymomonas mobilis in conventional submerged and solid-state fermentations | |
CN115521938A (en) | Coxsackie virus 10 type recombinant virus-like particle expression system, virus-like particles prepared by expression system and hand-foot-and-mouth disease vaccine | |
CN101892259B (en) | SiRNA plant gene expression vector and construction method and application thereof | |
CN111205989B (en) | Cladosporium sp-1 and application thereof in base wine aging | |
CN113684191A (en) | Pear head mould steroid 11 beta-hydroxylase CYP5311B2 mutant construction and application thereof | |
CN110484560B (en) | Method for producing barren-resistant rice containing HVUL2H20083.2 gene | |
CN111269842B (en) | Cladosporium sp-2 and application thereof in accelerating aging of new wine | |
CN114617189A (en) | Method for preparing compound protein feed by utilizing cassava vinasse liquid | |
CN116034163A (en) | Humic substances for producing erythritol |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |